Updated: Sep 17
Key Takeaways"Advanced cancer treatment in China" covers three distinct technologies, not one thing — proton/heavy-ion radiotherapy, immunotherapy, and targeted therapy. China's real edge is regulatory speed on specific drugs and a mature, lower-cost particle-therapy network — not a general claim of "better medicine." The seven drugs driving this access gap have published trial results, not just approval — objective response rates ranging roughly 45–96% depending on the drug and cancer, in heavily pretreated patient populations (detailed in the table below). Checkpoint-inhibitor efficacy appears broadly comparable between East Asian and non-East Asian patients in the best-studied cancer type (lung), though some targeted therapies do show real inter-ethnic differences — this is drug-specific, not something a general guide can promise either way. Several partner-type hospitals hold JCI accreditation — the international division of The Joint Commission, the same body that accredits the majority of hospitals in the United States — though accreditation and physician credentials should always be verified directly before treatment. |
Introduction
Many individuals searching for cancer treatment options have encountered similar messages from their oncologists. They may have been told that standard treatments have been exhausted or that the next available option involves significant trade-offs. This often leads them to explore alternative treatments, with "China" emerging as a potential destination. However, it is essential to understand that "advanced cancer treatment" is not a singular concept. It encompasses various technologies that operate differently, target distinct cancers, and share the commonality of being newer than traditional chemotherapy and surgery.
This guide aims to clarify the different categories of advanced cancer treatment available in China. It will detail what each category entails, which cancers and situations are relevant, associated costs, and the actual trial data supporting these treatments. Additionally, it will provide insights into how to determine if these options are suitable for individual cases.
It is also important to consider the alternatives to treatment in China. Options such as Korea, Singapore, or continuing standard treatments in the US, Canada, Australia, or New Zealand may also be viable. China's advantage lies not in offering "better medicine" but in its regulatory speed for specific drugs and a well-established, cost-effective particle therapy network. If China does not have a specific advantage for a given diagnosis, it may not be the best choice, and this guide will reflect that.
The Three Categories of Advanced Cancer Treatment in China
Proton and Heavy-Ion Therapy
Proton and heavy-ion (carbon-ion) therapy is a form of radiation treatment. It utilizes charged particles instead of X-rays, allowing for precise targeting of tumors while minimizing damage to surrounding healthy tissue. This treatment is particularly beneficial for tumors located near critical structures, such as the brain, spine, or head and neck, as well as for pediatric cancers where limiting radiation exposure is crucial.
Immunotherapy
Immunotherapy operates differently by enhancing the immune system's response to cancer. Checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4 drugs, block signals that cancer cells use to evade immune detection. Newer bispecific antibodies can target two signals simultaneously. Immunotherapy is most effective for cancers with specific biomarkers, such as MSI-H/dMMR status or certain PD-L1 expression levels, rather than being universally applicable.
Targeted Therapy
Targeted therapy encompasses a broader range of treatments, including antibody-drug conjugates (ADCs) that deliver chemotherapy directly to cancer cells expressing specific markers like HER2, and small-molecule drugs that inhibit mutated proteins driving cancer growth. Similar to immunotherapy, targeted therapy is only effective if the tumor possesses the specific target for the drug, necessitating biomarker testing prior to treatment.
Proton and Heavy-Ion Therapy: One Pillar of Advanced Cancer Treatment in China
China currently operates approximately a dozen proton and heavy-ion treatment centers listed in the Particle Therapy Co-Operative Group's public facilities registry, with more centers under construction. The Shanghai Proton and Heavy Ion Center (SPHIC), established in 2015, has treated thousands of patients and maintains a consistent treatment-package price of around 310,000 RMB (approximately $45,000 USD). A 2022 peer-reviewed review of China's particle therapy sector noted several operational facilities beyond Shanghai, including centers in Shandong and Guangdong, collectively treating nearly 8,000 patients.
SPHIC's published price is the most reliable figure available for a full proton or heavy-ion course; in contrast, treatment costs in the US typically range from $100,000 to $200,000, more than double SPHIC's rate. Pricing at other centers and for more complex tumor sites requiring additional sessions should be confirmed directly with the specific hospital, as treatment durations typically span 4 to 8 weeks depending on tumor location.
It is important to note that proton and heavy-ion therapy is not universally superior to standard radiation. It is most beneficial for tumors located near sensitive structures, certain pediatric cancers, and select head, neck, and spinal tumors. A radiation oncologist's evaluation of the specific tumor location will determine whether this technology is the best option for a given case.
Immunotherapy and Targeted Therapy: The Second Pillar of Advanced Cancer Treatment in China
This aspect of advanced cancer treatment in China evolves rapidly. The National Medical Products Administration (NMPA) has employed expedited review pathways, including priority reviews and conditional approvals, to bring various cell and gene therapies and novel biologic drugs to market. In some instances, these drugs become available in China years before they receive full approval in the US or Europe. Consequently, a notable gap exists: several immunotherapy and targeted-therapy drugs are commercially available and NMPA-approved in China for specific indications, such as recurrent cervical cancer and certain lymphomas, while their equivalents may still be undergoing mid-stage clinical trials in other countries.
This guide will not delve into each individual drug, as the details change frequently and warrant their own dedicated space. For the current list of NMPA-approved immunotherapy and targeted-therapy drugs available in China, along with the cancers and biomarker profiles each targets, refer to the companion guide to advanced therapies in China. Cellular therapies, specifically CD19 and BCMA CAR-T, are discussed in more detail in our dedicated guide to CAR-T cell therapy cost in China.
What the Trial Data Actually Shows
It is crucial to differentiate between the existence of a technology and its proven effectiveness. The seven drugs responsible for the access gap have published peer-reviewed or conference-presented trial results, not merely regulatory approval. The objective response rates for these drugs range from approximately 45% to 96%, depending on the drug and cancer type, in heavily pretreated patient populations.
A few key points to note regarding the data presented in the table below:
The objective response rates refer to specific patient populations enrolled in trials, which typically consist of heavily pretreated patients who have already exhausted standard treatment options. These rates are not directly comparable to first-line treatment statistics.
An objective response rate indicates that the tumor has measurably shrunk or disappeared on imaging. While this is a significant outcome, it does not equate to a cure rate. The durability of response varies by therapy, as indicated by the duration-of-response and progression-free survival figures where reported.
The numbers reflect how each drug performed in the trial population that led to its approval. They do not guarantee similar outcomes for individual patients, as results depend on case-specific factors.
How to Know Whether Advanced Cancer Treatment in China Applies to a Specific Case
Access to a therapy in China does not guarantee its suitability for every patient. Before any of the three categories above become realistic options, several factors typically need to be established:
Diagnosis and histology: The precise subtype of cancer, not just the general organ or tissue of origin.
Biomarker status: HER2 expression, MSI/dMMR status, PD-L1 expression, or the relevant target for the therapy being considered, confirmed through current testing rather than relying on older pathology reports.
Treatment history: The drugs or therapies that have already been tried and the cancer's response to each.
Organ function and overall fitness: Particularly relevant for immunotherapy (autoimmune risk) and particle therapy (ability to tolerate travel and a multi-week treatment course).
Goals of care: Whether the aim is curative treatment, disease control, or quality of life, as this influences which options are worth pursuing.
A therapy that could significantly benefit one patient may be irrelevant or unsafe for another with a seemingly similar diagnosis. Therefore, any serious consideration of advanced cancer treatment in China should begin with a physician-led review of the actual medical record, rather than a general search for available treatments.
Does Ethnicity Affect How These Therapies Work?
This question is valid, especially since these drugs were primarily developed and trialed in Chinese patient populations. The answer varies depending on the drug class, and the data is more reassuring for some categories than others.
For checkpoint inhibitors, the most extensive comparative evidence comes from lung cancer research. Multiple meta-analyses comparing East Asian and non-East Asian patients on PD-1/PD-L1 and CTLA-4 inhibitors have found broadly comparable response rates and survival outcomes between the groups. However, one review noted a higher rate of immune-related side effects reported in Japanese patients specifically, a pattern not consistently observed across other Asian populations. This is encouraging for the immunotherapy and bispecific-antibody drugs discussed here, although the studies were conducted in lung cancer, not necessarily the specific cancers each drug is approved for.
Targeted therapies present a different scenario, with less uniform reassurance. A review of tyrosine kinase inhibitor trials revealed real inter-ethnic differences in outcomes for some drugs. For instance, certain EGFR-targeted therapies have demonstrated better results in East Asian patients than in non-Asian patients in head-to-head trial subgroups, while for at least one newer-generation drug, the pattern reversed. This highlights the importance of biomarker and pharmacogenomic review, as the honest answer to "will this work the same for me" is drug-specific, rather than a general promise.
Where Advanced Cancer Treatment Happens in China
The phrase "China's top hospitals" is accurate but lacks specificity for families trying to verify where they would actually receive treatment. Joint Commission International (JCI) accreditation, the international division of The Joint Commission, which accredits the majority of hospitals in the United States, is held by a significant number of Chinese hospitals. A 2023 peer-reviewed study interviewing leadership at five JCI-accredited Chinese hospitals documented the reasons hospitals pursue accreditation and the operational changes that result, demonstrating that the accreditation reflects a genuine shift in quality and patient safety, rather than merely a marketing badge.
China's major public academic cancer centers, such as the National Cancer Center in Beijing, Peking University Cancer Hospital, and Sun Yat-sen University Cancer Center, are the highest-volume specialist centers for the cancers discussed here. They typically operate international/VIP departments for overseas patients, separate from JCI's private-hospital accreditation track.
The relevance of specific hospitals to a given case depends on the applicable therapy. Current accreditation status should always be verified directly against JCI's public accreditation directory before treatment, as hospital accreditation can change over time, and no article should serve as the final word on it.
How ChinaCureLink Helps With Advanced Cancer Treatment in China
Given how much the right option depends on case-specific details, most of what is useful occurs before any treatment decision:
Case review against all three categories at once: Rather than starting with "which technology sounds promising," your diagnosis, biomarkers, and treatment history are reviewed against what is actually available and appropriate — proton therapy, immunotherapy, targeted therapy, or none of the above.
A direct answer, not a sales conversation: The purpose of the initial review is to inform you plainly whether a relevant option exists for your case, including telling you if it does not, rather than keeping the door open indefinitely.
Hospital and specialist matching: Proton/heavy-ion centers, immunotherapy programs, and targeted-therapy prescribers are not all located at the same hospital. Matching connects a case to the specific center equipped for the relevant therapy.
Translation and documentation: Pathology reports, prior imaging, and treatment histories are translated and organized into the format Chinese specialists require for an efficient review.
Ongoing coordination: For cases that proceed, the same team handles travel and visa logistics and remains involved throughout treatment and follow-up, rather than handing off after the initial match.
Submitting a case for review is a way to discover what is realistically achievable — it does not commit you to treatment in China.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
Frequently Asked Questions
What counts as advanced cancer treatment in China?
In practice, three categories: proton and heavy-ion radiotherapy, immunotherapy (checkpoint inhibitors and bispecific antibodies), and targeted therapy (antibody-drug conjugates and small-molecule drugs). They work differently, treat different cancers, and aren't interchangeable.
How do I get started with advanced cancer treatment in China?
Through a case review that checks your diagnosis, biomarker status, and treatment history against what's actually available and appropriate — not by picking a technology first and asking whether you qualify for it.
Is proton therapy actually available in China, or is that overstated?
It's genuinely available and has been for over a decade — China operates roughly a dozen proton and heavy-ion centers currently listed as operational, the most established being the Shanghai Proton and Heavy Ion Center, open since 2015.
Why are some immunotherapy or targeted-therapy drugs available in China but not yet at home?
China's regulator has used expedited approval pathways for certain cell, gene, and biologic therapies, which has meant some drugs reach commercial approval in China years before the equivalent drug clears full approval elsewhere. This varies drug by drug and isn't universal.
How much does proton therapy cost in China compared to the US?
The Shanghai Proton and Heavy Ion Center publishes a flat package price of roughly $45,000 USD, versus commonly cited US ranges of $100,000–$200,000 for the same treatment — more than double SPHIC's rate. Pricing at other centers varies and should be confirmed directly.
Does advanced cancer treatment in China actually work, or is it unproven?
The seven specific drugs discussed above have published trial results, not just regulatory approval — objective response rates ranging roughly 45–96% depending on the drug and cancer type, in patients who had already exhausted standard treatment. See the trial-data table above for the specific numbers behind each therapy.
Do I need to travel to China to find out if I'm a candidate?
No — initial case review is typically done remotely, based on medical records, pathology, and imaging submitted electronically. Travel becomes relevant only once a specific therapy and hospital have been identified as appropriate.
References
Particle Therapy Co-Operative Group (PTCOG) — Facilities in Clinical Operation. https://www.ptcog.site/index.php/facilities-in-operation-public
China's first hospital with heavy ion, proton radiotherapies sets new records for patients treated — Global Times, 2023. https://www.globaltimes.cn/page/202304/1289019.shtml
Li Y, Li X, Yang J, et al. Flourish of Proton and Carbon Ion Radiotherapy in China. Frontiers in Oncology, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882681/
China's NMPA Approves First CAR T-Cell Therapy for CLDN18.2+, HER2- Advanced Gastric/GEJ Adenocarcinoma — OncLive, 2026. https://www.onclive.com/view/china-s-nmpa-approves-first-car-t-cell-therapy-for-cldn18--2-her2-advanced-gastric-gej-adenocarcinoma
Xie Y, Zhou K, Li L, et al. Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults. Blood Advances, 2026. https://ashpublications.org/bloodadvances/article/10/4/1134/546727
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy (citing equeca-cel comparator data). Experimental Hematology & Oncology, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12482220/
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma. Experimental Hematology & Oncology, 2025. https://link.springer.com/article/10.1186/s40164-025-00710-y
Efficacy and Safety of Disitamab Vedotin in Patients With HER2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials. Journal of Clinical Oncology. https://ascopubs.org/doi/10.1200/JCO.22.02912
Efficacy and safety of Cadonilimab in the treatment of recurrent/metastatic and advanced cervical cancer: a systematic review and meta-analysis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12832733/
10. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. Journal of Hematology & Oncology, 2021. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218452/
11. Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients with relapsed/refractory CLL/SLL who had failed BTK inhibitors. Blood (ASH Annual Meeting abstract), 2025. https://www.sciencedirect.com/science/article/pii/S0006497125026631
12. Peng L, et al. A meta-analysis on immune checkpoint inhibitor efficacy for advanced NSCLC between East Asians versus non-East Asians. Translational Lung Cancer Research, 2020. https://tlcr.amegroups.org/article/view/41958/html
13. Lee J, Sun JM, Lee SH, et al. Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer? Journal of Thoracic Disease, 2020. https://pubmed.ncbi.nlm.nih.gov/32802459/
14. Inter-Ethnic Differences in the Efficacy and Safety of Tyrosine Kinase Inhibitors Used in Oncology: Insights From Phase 3 Clinical Trials. https://pmc.ncbi.nlm.nih.gov/articles/PMC12037692/
15. About Joint Commission International — Joint Commission. https://www.jointcommission.org/en-us/about-us/jci
16. Zhang H, Huang ST, Bittle MJ, et al. Perceptions of Chinese hospital leaders on Joint Commission International accreditation: a qualitative study. Frontiers in Public Health, 2023. https://pubmed.ncbi.nlm.nih.gov/37965503/
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad. We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia-Pacific, bringing the same standard of expert care coordination to every patient we serve.
This article is for informational purposes only and is not medical advice. Treatment suitability depends on individual diagnosis, biomarker status, and treatment history. Confirm all details with a patient coordinator and a treating oncologist before making any decisions.
Comments